2020 review – Pharma’s progress outside of COVID-19
pharmaphorum
DECEMBER 23, 2020
It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout. Rare disease progress.
97 
Let's personalize your content